Striatal dopamine D2/3 receptor availability in treatment resistant depression

Several studies demonstrated improvement of depressive symptoms in treatment resistant depression (TRD) after administering dopamine agonists which suggest abnormal dopaminergic neurotransmission in TRD. However, the role of dopaminergic signaling through measurement of striatal dopamine D(2/3) rece...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2014-11, Vol.9 (11), p.e113612-e113612
Main Authors: de Kwaasteniet, Bart P, Pinto, Chedwa, Ruhé, Henricus G, Ruhé, Eric H G, van Wingen, Guido A, Booij, Jan, Denys, Damiaan
Format: Article
Language:English
Subjects:
Adolescent
Adult
Aged
Antidepressants
Antipsychotic Agents - therapeutic use
Antipsychotics
Availability
Binding
Biology and Life Sciences
Case-Control Studies
Computed tomography
Corpus Striatum - diagnostic imaging
Corpus Striatum - metabolism
Depressive Disorder, Treatment-Resistant - drug therapy
Depressive Disorder, Treatment-Resistant - pathology
Dopamine
Dopamine D2 Receptor Antagonists - chemistry
Dopamine D2 receptors
Emission analysis
Female
Humans
Iodobenzenes - chemistry
Male
Medical imaging
Medicine and Health Sciences
Mental depression
Middle Aged
Neostriatum
Neurotransmission
Patients
Photon emission
Psychotropic drugs
Radiopharmaceuticals - chemistry
Receptors, Dopamine D2 - chemistry
Receptors, Dopamine D2 - metabolism
Receptors, Dopamine D3 - chemistry
Receptors, Dopamine D3 - metabolism
Signaling
Single photon emission computed tomography
Studies
Tomography, Emission-Computed, Single-Photon
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Several studies demonstrated improvement of depressive symptoms in treatment resistant depression (TRD) after administering dopamine agonists which suggest abnormal dopaminergic neurotransmission in TRD. However, the role of dopaminergic signaling through measurement of striatal dopamine D(2/3) receptor (D2/3R) binding has not been investigated in TRD subjects. We used [(123)I]IBZM single photon emission computed tomography (SPECT) to investigate striatal D2/3R binding in TRD. We included 6 severe TRD patients, 11 severe TRD patients on antipsychotics (TRD AP group) and 15 matched healthy controls. Results showed no significant difference (p = 0.75) in striatal D2/3R availability was found between TRD patients and healthy controls. In the TRD AP group D2/3R availability was significantly decreased (reflecting occupancy of D2/3Rs by antipsychotics) relative to TRD patients and healthy controls (p
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0113612